E Fund Management Co., Ltd. Zentalis Pharmaceuticals, Inc. Transaction History

E Fund Management Co., Ltd.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$4.09 - $16.13 $15,975 - $63,003	-3,906 Reduced 27.74%	10,177 $41,000
Q1 2024 May 13, 2024	SELL	$10.83 - $16.49 $56,933 - $86,687	-5,257 Reduced 27.18%	14,083 $221,000
Q4 2023 Feb 06, 2024	BUY	$9.84 - $20.13 $88,884 - $181,834	9,033 Added 87.64%	19,340 $293,000
Q3 2023 Nov 13, 2023	SELL	$19.63 - $28.29 $62,521 - $90,103	-3,185 Reduced 23.61%	10,307 $207,000
Q2 2023 Aug 11, 2023	BUY	$17.41 - $30.05 $29,092 - $50,213	1,671 Added 14.14%	13,492 $381,000
Q1 2023 May 11, 2023	SELL	$16.14 - $24.94 $3,147 - $4,863	-195 Reduced 1.62%	11,821 $203,000
Q4 2022 Feb 14, 2023	SELL	$18.07 - $25.6 $11,058 - $15,667	-612 Reduced 4.85%	12,016 $242,000
Q3 2022 Nov 14, 2022	SELL	$20.23 - $31.73 $34,957 - $54,829	-1,728 Reduced 12.04%	12,628 $274,000
Q2 2022 Aug 15, 2022	BUY	$17.91 - $52.25 $148,241 - $432,473	8,277 Added 136.16%	14,356 $403,000
Q1 2022 May 12, 2022	BUY	$41.58 - $80.89 $139,417 - $271,224	3,353 Added 123.0%	6,079 $280,000
Q1 2021 May 12, 2021	BUY	$35.69 - $52.72 $97,290 - $143,714	2,726 New	2,726 $118,000

142

68M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $170M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management Co., Ltd. with notifications on news.